To gain new knowledge on the environmental safety of pharmaceuticals, consequently improving appraisal of the issue and reducing emissions of pharmaceuticals in the environment
The project entails the following activities: 1) IMI iPIE project: the identification of the potential environmental risks of existing and new active pharmaceutical ingredients (API) through intelligent and targeted assessment strategies; 2) Manufacturing effluents management: the compilation of best industry practices enabling manufacturers to minimize risks to the environment; 3) Extended ERA: the refinement of the existing environmental risk assessment (ERA) process for medicinal products to ensure that they remain up-to-date and relevant
- Eco-Pharmaco-Stewardship (EPS). A holistic environmental risk management program
- Eco-Pharmaco-Stewardship (EPS). Pillar 1 – Research and development: Intelligence-led Assessment of Pharmaceuticals in the Environment (iPiE)
- Eco-Pharmaco-Stewardship (EPS). Pillar 3 – Extended Environmental Risk Assessment (eERA)
- Eco-Pharmaco-Stewardship (EPS). Pillar 2 – Manufacturing: effluent management
- Inter-Association Industry Initiative: Eco-Pharmaco-Stewardship (EPS)
- Webinar on the Eco-Pharmaco-Stewardship (EPS) proposal
HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.
